Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies

Willie Earley, Suresh Durgam, Kaifeng Lu, István Laszlovszky, Marc Debelle, John M Kane, Willie Earley, Suresh Durgam, Kaifeng Lu, István Laszlovszky, Marc Debelle, John M Kane

Abstract

Cariprazine, a potent dopamine D3 and D2 receptor partial agonist antipsychotic with preferential binding to D3 receptors, is Food and Drug Administration approved for treating schizophrenia and manic or mixed episodes of bipolar I disorder. A post-hoc safety/tolerability analysis of data from the four acute trials in the cariprazine schizophrenia clinical development program (NCT00404573; NCT00694707; NCT01104766; NCT01104779) was carried out using the overall safety population (all patients who received ≥1 dose of study drug) and modal daily dose subgroups (1.5-3, 4.5-6, and 9-12 mg/day). These exploratory findings were summarized using descriptive statistics. Cariprazine was generally well tolerated. The incidence of treatment-emergent adverse events versus placebo was similar for cariprazine 1.5-3 mg/day and higher for cariprazine 4.5-6 and 9-12 mg/day; a dose-response relationship was observed for akathisia, extrapyramidal symptoms, and diastolic blood pressure. The mean changes in metabolic parameters were generally similar in cariprazine-treated and placebo-treated patients. There was no prolactin level increase or QTc value greater than 500 ms; small increases in mean body weight (∼1to2 kg) versus placebo were observed. Within the Food and Drug Administration-approved dose range (1.5-6 mg/day), cariprazine was generally safe and well tolerated in patients with schizophrenia.

References

    1. Abilify (2014). Prescribing information; Princeton, NJ. Rockville, MD: Otsuka America Pharmaceuticals Inc.
    1. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision. Washington, DC: American Psychiatric Association.
    1. Barnes TR. (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676.
    1. Caroff SN, Mann SC, Campbell EC, Sullivan KA. (2002). Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 63 (Suppl 4): 12–19.
    1. Cha DS, Mcintyre RS. (2012). Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin Pharmacother 13:1587–1598.
    1. Durgam S, Starace A, Li D, Migliore R, Ruth A, Nemeth G, et al. (2014). An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res 152:450–457.
    1. Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, et al. (2015). Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry 76:e1574–e1582.
    1. Durgam S, Litman RE, Papadakis K, Li D, Nemeth G, Laszlovszky I. (2016). Cariprazine in the treatment of schizophrenia: a proof-of-concept trial. Int Clin Psychopharmacol 31:61–68.
    1. Farah A. (2005). Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry 7:268–274.
    1. Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, et al. (2016). Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO. Psychopharmacology (Berl) 233:3503–3512.
    1. Goff DC, Cather C, Evins AE, Henderson DC, Freudenreich O, Copeland PM, et al. (2005). Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 66:183–194.
    1. Guy W. (1976a). The Abnormal Movement Scale, ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institutes of Mental Health; 218–222.
    1. Guy W.Guy W. (1976b). Clinical global impressions. ECDEU assessment manual for psychopharmacology: publication ADM. Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch; 76–338.
    1. Gyertyan I, Saghy K, Laszy J, Elekes O, Kedves R, Gemesi LI, et al. (2008). Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol 378:529–539.
    1. Gyertyan I, Kiss B, Saghy K, Laszy J, Szabo G, Szabados T, et al. (2011). Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int 59:925–935.
    1. Henderson DC, Doraiswamy PM. (2008). Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry 69 (Suppl 1): 32–44.
    1. Hennekens CH. (2007). Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J Clin Psychiatry 68 (Suppl 4):4–7.
    1. Kane JM, Sharif ZA. (2008). Atypical antipsychotics: sedation versus efficacy. J Clin Psychiatry 69 (Suppl 1):18–31.
    1. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A, 3rd, Assuncao-Talbott S. (2009). Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 70:627–643.
    1. Kane JM, Barnes TR, Correll CU, Sachs G, Buckley P, Eudicone J, et al. (2010). Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J Psychopharmacol 24:1019–1029.
    1. Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K, et al. (2015). Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol 35:367–373.
    1. Kay SR, Fiszbein A, Opler LA. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276.
    1. Kiss B, Laszlovszky I, Horvath A, Nemethy Z, Schmidt E, Bugovics G, et al. (2008). Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol 378:515–528.
    1. Kiss B, Horvath A, Nemethy Z, Schmidt E, Laszlovszky I, Bugovics G, et al. (2010). Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 333:328–340.
    1. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. (2010). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull 36:94–103.
    1. Kumar R, Sachdev PS. (2009). Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry 22:293–299.
    1. Laszy J, Laszlovszky I, Gyertyan I. (2005). Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology (Berl) 179:567–575.
    1. Latuda (2013). Prescribing information. Marlborough, MA: Sunovion Pharmaceuticals Inc.
    1. Lehman AF, Lieberman JA, Dixon LB, Mcglashan TH, Miller AL, Perkins DO, et al. (2004). Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161:1–56.
    1. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41.
    1. Miller DD, Caroff SN, Davis SM, Rosenheck RA, Mcevoy JP, Saltz BL, et al. (2008). Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 193:279–288.
    1. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. (2005). Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79–104.
    1. Newcomer JW. (2007). Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 68 (Suppl 4):8–13.
    1. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. (2011). The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168:1266–1277.
    1. Poyurovsky M. (2010). Acute antipsychotic-induced akathisia revisited. Br J Psychiatry 196:89–91.
    1. Riordan HJ, Antonini P, Murphy MF. (2011). Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications. Am Health Drug Benefits 4:292–302.
    1. Risperdal (2014). Prescribing information. Titusville, NJ: Janssen LP.
    1. Saha S, Chant D, Mcgrath J. (2007). A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 64:1123–1131.
    1. Saphris (2014). Prescribing information. St Louis, MO: Forest Pharmaceuticals Inc.
    1. Schwartz JC, Diaz J, Pilon C, Sokoloff P. (2000). Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res Brain Res Rev 31:277–287.
    1. Simpson GM, Angus JW. (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11–19.
    1. Stanniland C, Taylor D. (2000). Tolerability of atypical antipsychotics. Drug Saf 22:195–214.
    1. Tandon R. (2002). Safety and tolerability: how do newer generation "atypical" antipsychotics compare? Psychiatr Q 73:297–311.
    1. Zyprexa (2011). Prescribing information. Indianapolis, IN: Eli Lily and Company.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren